NCT00116129View on ClinicalTrials.gov

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

April 30, 2008

Conditions
Fibromyalgia
Interventions
DRUG

Ibutamoren Mesylate (MK-0677)

Ibutamoren Mesylate 25 mg/day

Trial Locations (1)

97239

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Bennett, Robert, M.D.

INDIV

NCT00116129 - Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia | Biotech Hunter | Biotech Hunter